Literature DB >> 3604394

Liposomes as immunological adjuvants: antigen incorporation studies.

G Gregoriadis, D Davis, A Davies.   

Abstract

Tetanus toxoid was incorporated into liposomes composed of equimolar phospholipid and cholesterol. The toxoid was either passively entrapped into multilamellar vesicles prepared by the dehydration-rehydration procedure (DRV) or covalently coupled by diazotization to the surface of multilamellar vesicles (MLV) prepared by the classical procedure. Up to 82.3% of the antigen used was entrapped in neutral, negatively and positively charged DRV composed of a variety of unsaturated and saturated phospholipids and 63.1% was coupled to MLV composed of egg phosphatidylcholine. After freeze-drying of toxoid-incorporating DRV and MLV and subsequent rehydration, up to 93.5% of the antigen was recovered with liposomes and, in the case of MLV, retained its external localization. Upon freeze-drying in the presence of 0.25 M trehalose, up to 96.1% of the antigen was recovered with the DRV liposomes. In immunization studies using Balb/c mice, DRV composed of equimolar egg phosphatidylcholine and cholesterol were shown to act as immunological adjuvants to the entrapped tetanus toxoid. In addition, there was no difference in immune responses between DRV and MLV of identical composition but bearing the toxoid on their surface. Comparison of immune responses to the toxoid entrapped in DRV made of phospholipids with varying gel to liquid crystalline transition temperature (Tc) revealed a reduction in responses to very low or nil values for DRV made of distearoyl phosphatidylcholine (Tc 54 degrees C).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3604394     DOI: 10.1016/0264-410x(87)90063-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

Review 1.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

Authors:  Douglas S Watson; Aaron N Endsley; Leaf Huang
Journal:  Vaccine       Date:  2012-02-02       Impact factor: 3.641

2.  Induction of primary antigen-specific immune reponses in SCID-hu-PBL by coupled T-B epitopes.

Authors:  P Ifversen; C Mårtensson; L Danielsson; C Ingvar; R Carlsson; C A Borrebaeck
Journal:  Immunology       Date:  1995-01       Impact factor: 7.397

Review 3.  Optimal delivery of vaccines: clinical pharmacokinetic considerations.

Authors:  S Gizurarson
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

4.  The role of macrophages in the immunoadjuvant action of liposomes: effects of elimination of splenic macrophages on the immune response against intravenously injected liposome-associated albumin antigen.

Authors:  D Su; N Van Rooijen
Journal:  Immunology       Date:  1989-03       Impact factor: 7.397

5.  Immunopotentiation of the humoral response by liposomes: encapsulation versus covalent linkage.

Authors:  E Shahum; H M Thérien
Journal:  Immunology       Date:  1988-10       Impact factor: 7.397

6.  Immunogenicity of liposomes and iscoms containing the major outer membrane protein of Neisseria gonorrhoeae: influence of protein content and liposomal bilayer composition.

Authors:  G F Kersten; A M van de Put; T Teerlink; E C Beuvery; D J Crommelin
Journal:  Infect Immun       Date:  1988-06       Impact factor: 3.441

Review 7.  Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems.

Authors:  John C Kraft; Jennifer P Freeling; Ziyao Wang; Rodney J Y Ho
Journal:  J Pharm Sci       Date:  2013-11-25       Impact factor: 3.534

8.  Primary immune response to liposomal tetanus toxoid in mice: the effect of mediators.

Authors:  D Davis; G Gregoriadis
Journal:  Immunology       Date:  1989-10       Impact factor: 7.397

9.  Interleukin-2-containing liposomes: interaction of interleukin-2 with liposomal bilayers and preliminary studies on application in cancer vaccines.

Authors:  J J Bergers; W Den Otter; H F Dullens; C T Kerkvliet; D J Crommelin
Journal:  Pharm Res       Date:  1993-12       Impact factor: 4.200

10.  Mannose-mediated targeted immunoadjuvant action of liposomes.

Authors:  N Garcon; G Gregoriadis; M Taylor; J Summerfield
Journal:  Immunology       Date:  1988-08       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.